china buying into genome sequencing, page-24

Sorry you're out Aptayl.

The buy side has been weak for several months now. I suspect that this has a lot to do with the absence of the day traders. BLT used to have about 4M shares slushing around that day traders sold backwards and forwards and the sp varied accordingly. This made the buy side seem good but hid the real weakness, ie the absence of genuine buyers. A few months ago, about the time that Tacere announced its primate studies, a number of shareholders like myself picked up a lot of those 4M free floating shares and held on to them. This seemed to take the steam out of the day traders and they have exited the stock.

That announcement made no positive difference to the sp and, with no one else interested the underlying weakness has been exposed. I think this weakness has been there for some time but it was consolidated when all of our programs had their timetables extended substantially. Remember, before the last capital raising the pain program was supposed to be in the clinic at the end of this year. Only two months after the capital raising, the dates had blow out to the end of next year. I am sure that if the program had kept to the original timetable there would have been more buyers and a higher sp.

I know PF is aware of this 'lack of buyer interest' problem and Carl's appointment was a measure taken to fix it. Until he brings in a deal that has $ associated with it the sp will drag its chain. When the deal does drop, the rise in the sp will catch out many who have exited the stock. I hope that is not you and the we still see you on HC.